Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System

Andrew V. Kossenkov1, Anil Vachani2, Celia Chang1, Calen Nichols1, Shere Billoquin1, Wenhwai Horng1, William N. Rom3, Steven M. Albelda2, Michael K. Showe1, and Louise C. Showe1

Abstract

Purpose: To characterize the interactions of non–small cell lung cancer (NSCLC) tumors with the immune system at the level of mRNA and microRNA (miRNA) expression and to define expression signatures that characterize the presence of a malignant tumor versus a nonmalignant nodule.

Experimental Design: We have examined the changes of both mRNA and miRNA expression levels in peripheral blood mononuclear cells (PBMC) between paired samples collected from NSCLC patients before and after tumor removal using Illumina gene expression arrays.

Results: We found that malignant tumor removal significantly changes expression of more than 3,000 protein-coding genes, especially genes in pathways associated with suppression of the innate immune response, including natural killer cell signaling and apoptosis-associated ceramide signaling. Binding sites for the ETS domain transcription factors ELK1, ELK4, and SPI1 were enriched in promoter regions of genes upregulated in the presence of a tumor. Additional important regulators included five miRNAs expressed at significantly higher levels before tumor removal. Repressed protein-coding targets of those miRNAs included many transcription factors, several involved in immunologically important pathways. Although there was a significant overlap in the effects of malignant tumors and benign lung nodules on PBMC gene expression, we identified one gene panel which indicates a tumor or nodule presence and a second panel that can distinguish malignant from nonmalignant nodules.

Conclusions: A tumor presence in the lung influences mRNA and miRNA expression in PBMC and this influence is reversed by tumor removal. These results suggest that PBMC gene expression signatures could be used for lung cancer diagnosis. Clin Cancer Res; 17(18); 5867–77. ©2011 AACR.

Introduction

Lung cancer is the most common cause of cancer mortality worldwide, accounting for 222,520 new cases and 157,300 cancer deaths in the United States alone in 2010 (1). The overall 5-year survival for lung cancer is 16%, and prognosis is strongly correlated with the stage of disease at diagnosis (2). Only 15% of patients with lung cancer have localized disease at the time of diagnosis, leading to generally poor outcomes. Although chemotherapy and radiation therapy can be used, these modalities are primarily palliative producing only small increases in survival.

Understanding the role of the immune system in controlling tumor development and harnessing its capabilities for target detection and cell killing to develop new human cancer treatments are major challenges of substantial interest to researchers (3–5). Most proposed therapeutic approaches have been based on findings that the immune system can discriminate cancer cells from normal cells via tumor antigen recognition and secondary immune responses mediated by B- or T cells associated with the tumors (4, 6–8). These studies focus primarily on antigen-specific T-cell responses (3–4, 6–8). Aspects of the innate immune response could potentially also be used for cancer immunotherapy, but this approach has been similarly ineffective in part because tumors downregulate surface MHC molecules targeted in a primary response. Further knowledge of the effect of a tumor on gene expression by the immune system is needed to effectively apply immune therapeutic approaches.

Gene expression profiling provides a powerful approach to detecting the nature of interactions between the immune system and tumor components in patients, capturing
information useful for cancer diagnosis, prognosis, or new therapy development. Although this approach cannot be applied to human studies of immune cell interactions that sample tumors, the peripheral immune system can provide continuous information on these interactions. For example, we recently showed that a diagnostic gene expression signature of 29 genes measured in peripheral blood mononuclear cells (PBMC) was able to distinguish early-stage non–small cell lung cancer (NSCLC) patients from control patients that had nonmalignant lung disease with 86% accuracy. We also found that lung squamous cell carcinomas (LSCC) have a distinguishable and stronger PBMC-derived cancer signature than lung adenocarcinomas (LAC), indicating there is a specificity in the immune response to the presence of these 2 NSCLC tumor types (9). Detailed characterization of such responses might lead to new measures for diagnosis and prognosis and new therapeutic modalities.

To directly assess the effects of lung tumors on gene expression in the peripheral immune system, we initially measured the effect of surgical removal of lung tumors on the intensity of the 29-gene NSCLC signature in paired samples from 18 NSCLC patients that were taken before and then after tumor resection. We found that the tumor-associated signature was significantly reduced postsurgery in a majority of the paired samples tested (14/18 pairs). This signature reduction was independent of patient demographics, including postsurgery time of sampling. This observation supported our hypothesis that the 29-gene PBMC cancer signature was indeed a surrogate marker for the tumor presence. In this study, we have directly analyzed the nature of the global changes in PBMC gene expression that occur as a result of lung tumor removal. We have identified alterations in coding and noncoding gene expression profiles using paired pre- versus posttumor excision surgery PBMC samples. We identify changes associated with important immune functions that characterize the lung tumor presence and that distinguish malignant tumors from benign lung nodules. These studies show that in addition to the effects of a lung tumor on its associated immune cells, effects of the tumor in the lung can also be detected in the peripheral immune system. Our study addresses the changes in gene expression on this immune global environment that occur with surgical removal of the tumor.

**Materials and Methods**

**Study populations**

Study participants were recruited from the University of Pennsylvania Medical Center (Penn) from 2003 through 2007 from the Penn Institutional Review Board’s approved lung cancer study. Patients were newly diagnosed with histopathologically confirmed NSCLC and no prior history of cancer or cancer treatment.

**PBMC collection**

Blood was collected from lung cancer patients preoperatively and 1 to 5 months after surgery. Blood was drawn into 2 CPT tubes (BD). PBMC isolated within 90 minutes, washed in PBS, transferred into RNAlater (Ambion), and stored at 4°C overnight before transfer to −80°C.

**Microarrays for mRNA and miRNA**

RNA purification was carried out at the Wistar Genomics facility as previously reported (9), controlled for quality using the Bioanalyzer (Agilent). For mRNA gene expression, 400 ng of total RNA was amplified as recommended by Illumina and hybridized to the Illumina WG-6v2 human arrays. For miRNA expression, 500 ng of RNA was analyzed on the Illumina MI-12v2 arrays. Expression levels were extracted with BeadStudio v.3.0 software. Arrays were quantile normalized and filtered to remove noninformative probes as previously described (9). mRNA data are available in GEO as GSE13255 and miRNA as GSE27606.

**Pairwise t test**

mRNA and miRNA expression data for 18 pre/postsample pairs (11 pairs for miRNA) was tested for differential expression using 2-tail pairwise t test, with significance set to less than 0.05. False discovery rate (FDR) was calculated according to the Storey procedure (10).

**SVM-RFE**

A list of ranked genes was obtained using linear kernel support vector machine with recursive feature elimination (SVM-RFE; ref. 11) with 10-fold and 10× resampling cross-validation. Each crossvalidation iteration started with the 1,000 genes, most significant by t test, and the number of genes was reduced by 10% at each feature elimination step. Final ranking of the genes was done using a Borda count procedure (12).
**Quantitative real-time PCR**

Validation of array results was carried out using the TaqMan system (Applied Biosystems), as recommended, in an ABI 7900HT PCR System. Each sample was analyzed in duplicate and samples with CVs between replicates that were more than 0.5ΔCt were repeated.

**Ingenuity pathway analysis**

Pathway and functional analysis was carried out with Ingenuity Pathways Analysis (IPA) software (http://www.ingenuity.com/) using Ingenuity Core Analysis (IPA 6.0; Ingenuity Systems), corrected for multiple comparisons by Benjamini–Hochberg, using P < 0.05 as a significance threshold.

**DAVID enrichment analysis**

Enrichments of gene ontology (GO) terms, KEGG, and BIOCARTA pathways along with Swiss-Prot, INTERPRO, and SMART keywords in a gene list were done with DAVID software. Results were filtered to satisfy FDR less than 5% and fold enrichment more than 1.5 criteria.

**miRNA target detection**

Computationally predicted targets for a miRNA were derived from the union of results of target scanner software provided by Sanger (http://microrna.sanger.ac.uk) or Sloan-Kettering (http://www.microrna.org) databases (scans based on miRanda software), as well as Pictar (http://pictar.mdc-berlin.de) and TargetScan (http://www.targetscan.org). Overlap with gene expression data was done using Entrez Gene (http://www.ncbi.nlm.nih.gov/gene). A computationally predicted target gene was accepted only if it was significantly downregulated in presurgery samples as assessed by 1-tailed, paired t test with significance threshold of P < 0.05.

**Transcription factor motifs**

The web interface of Pscan was used to find enriched TRANSFAC motifs in −450 to +50 bp region from the transcriptional start site of genes from the SVM list. Bonferroni correction was used to rank the results, using a significance threshold of P < 0.05. For each motif, the top 500 scored genes were used to determine whether enrichment of up- versus downregulated genes occurred in the list.

**Additional statistical tests**

The following tests were used to determine significance of results, using a threshold of P < 0.05.

Spearman correlation: correlation of ranks between 2 gene lists generated by SVM-RFE and paired t test.

Pearson correlation: correlation between expression ratios in pre-/postsurgery sample pairs versus cancer/noncancer samples.

Fisher exact test: enrichment of an annotation term within a gene list; overrepresentation of up- or downregulated genes in a list of cell type–specific genes from IRIS database.

### Table 1. Pre–post patient demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>68</td>
</tr>
<tr>
<td>Max</td>
<td>87</td>
</tr>
<tr>
<td>Min</td>
<td>47</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>10</td>
</tr>
<tr>
<td>Female</td>
<td>8</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>17</td>
</tr>
<tr>
<td>AA</td>
<td>1</td>
</tr>
<tr>
<td>Tobacco use</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>15</td>
</tr>
<tr>
<td>Current</td>
<td>1</td>
</tr>
<tr>
<td>Never</td>
<td>2</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>LAC</td>
<td>10</td>
</tr>
<tr>
<td>LSCE</td>
<td>6</td>
</tr>
<tr>
<td>NSCLC</td>
<td>2</td>
</tr>
<tr>
<td>Cancer stage</td>
<td></td>
</tr>
<tr>
<td>I/II</td>
<td>11</td>
</tr>
<tr>
<td>III/IV</td>
<td>7</td>
</tr>
<tr>
<td>Sampling time from surgery</td>
<td></td>
</tr>
<tr>
<td>1–2 mo</td>
<td>12</td>
</tr>
<tr>
<td>3–5 mo</td>
<td>6</td>
</tr>
<tr>
<td>COPD</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>7</td>
</tr>
<tr>
<td>No</td>
<td>11</td>
</tr>
</tbody>
</table>

NOTE: All tumors, including stage 3 and 4, were completely resected.

Abbreviations: AA, African American; NSCLC, unclassified; COPD, chronic obstructive pulmonary disease.

Hypergeometric test: overlap between significantly expressed genes in pre-/postsurgery, cancer/noncancer, and cancer/benign nodule patient sample comparisons.

### Results

**Patient samples and demographics**

PBMC from the 18 patients were collected in the University of Pennsylvania Medical Center. Clinical and demographic variables for those patients are shown in Table 1. Samples were collected with IRB approval, as previously described (9). Presurgery samples were collected on the day of resection just prior to surgery. Times of postsurgery sample collection ranged from 1 to 5 months. Most (n = 10) patients were sampled 2 months after surgery and the others sampled at 1, 3, 4, or 5 months postsurgery. All samples were collected before any additional therapy was started. A more complete description of patients and staging information is shown in Supplementary Table S1.
**PBMC gene expression is altered by lung tumor removal.** Expression data for the 18 pairs of pre-/postsurgery PBMC samples were generated using Illumina HGv2 bead arrays (Illumina, Inc.). The data were analyzed using the SVM-RFE and 10-fold crossvalidation repeated 10 times as previously described (9). This approach generated a list of 3,271 genes ranked by ability to discriminate pre- from postsurgery samples. Sixty-seven percent of those genes were more highly expressed presurgery (i.e., in the presence of tumor). An expression heatmap of the 50 highest ranked genes is shown in Figure 1. Expression values of only the 4 genes with the highest ranking were needed to separate pre- and postsurgery samples with 100% accuracy (sensitivity and specificity = 100%) as determined by 10-fold crossvalidation. We also analyzed the data by paired t test and identified 2,897 genes showing significant differential expression (P < 0.05, FDR of 17%). When ranked by P value, 81% of the t-test significant genes overlapped with the SVM-generated gene list, and their ranks correlated at rho = 0.39 with the SVM ranking. The 3 genes highest ranked by SVM-RFE were also those highest ranked by paired t test and included CYP2R1 (a p-450 microsomal vitamin D hydroxylase), MYO5B (mitochondrial 3-oxoacyl-coenzyme A thiolase), and DGUOK (mitochondrial deoxyguanosine kinase). All 3 were expressed at higher levels pre- versus postsurgery. Expression patterns of CYP2R1 and DGUOK were validated by quantitative real-time PCR on 10 of the pre-/postsurgery sample pairs (Supplementary Table S2). We used the gene list identified using SVM-RFE for all further analyses. Because 2 of the 3 most significant genes identified by both methods have mitochondrial functions, we determined whether mitochondria-associated genes were overrepresented in our significant gene list. We found a 1.6-fold enrichment of genes having mitochondrial annotations (P = 2 × 10^{-11}). Eighty percent (111/139) of the differentially expressed mitochondrial genes were upregulated pre- versus postsurgery, suggesting that PBMC had increased metabolic activity when tumors were present. Enriched functional categories identified using
ERK, extracellular signal regulated kinase; MAPK, mitogen-activated protein kinase.

The sphingosine-1-phosphate receptor 5 (S1PR5), which is specifically expressed in NK cells and T cells (further supporting NK cell involvement), and ErbB signaling pathways were upregulated in presurgery samples (Supplementary Table S4). These included ceramide signaling, which is a second messenger that suppresses NK function. The ceramide signaling pathway was the second most significantly enriched. Ceramide is a second messenger that is important for NK and NKT cell functions (17–19). As an inducer of apoptosis, it can act through a variety of signaling molecules to induce cell death (20). Eleven of the 17 identified genes associated with ceramide signaling were upregulated in presurgery samples (Supplementary Table S4), including 22 that were expressed at higher levels, suggesting an increased functional activity of ceramide signaling in the presence of a NSCLC tumor.

DAVID (http://david.abcc.ncifcrf.gov/) software included additional metabolic processes and genes associated with protein processing (Supplementary Table S3).

Tumor removal alters expression of genes associated with immune functions

We used Ingenuity Core Analysis (Ingenuity Systems Inc.) to identify the functions and pathways significantly enriched in the SVM-generated gene list. Genes and pathways associated with specific immune functions are well represented, including genes important for the generation of memory T cells, T-cell accumulation, and the mobilization of natural killer (NK) cells. Among the 6 pathways showing significant enrichment, 5 are signaling pathways, the 3 most significant of which were NK cell, ceramide, and ErbB signaling pathways ($P = 3 \times 10^{-6}$, $7 \times 10^{-3}$, and $2 \times 10^{-2}$, respectively; Fig. 2).

Highly significant changes occurred in expression levels of 29 genes associated with NK cell signaling (Supplementary Table S4), including 22 that were expressed at higher levels in the presurgery samples. Seven of these 22 genes encode long-form members of the KIR receptor family, which are known to suppress NK signaling (13, 14), suggesting that tumor presence induces an environment that suppresses NK function.

The ceramide signaling pathway was the second most significantly enriched. Ceramide is a second messenger that affects apoptosis, metabolism, differentiation, and senescence (15, 16) and is important for NK and NKT cell functions (17–19). As an inducer of apoptosis, it can act through a variety of signaling molecules to induce cell death (20). Eleven of the 17 identified genes associated with ceramide signaling were upregulated in presurgery samples (Supplementary Table S4). These included ceramide kinase (CERK), which is specifically expressed in NK cells and T cells (further supporting NK cell involvement), the sphingosine-1-phosphate receptor 5 (SIPR5), sphingomyelin phosphodiesterase 3 (SMPD3), and the pro-apoptotic gene BAD, also shared with the ErbB/neuregulin pathway. Taken together, these results suggest a heightened susceptibility of one or more PBMC lineages to apoptosis in the presence of a NSCLC tumor.

Enriched transcription factor–binding sites in promoters regions of genes differentially expressed in PBMC after lung tumor removal

To assess whether common transcription factors might influence differential gene expression, we scanned the promoter regions of the 3,271 SVM-identified genes for enrichment in transcription factor–binding motifs. We identified 13 transcription factor–binding sites that were significantly overrepresented (Supplementary Table S5) within the promoters of genes that were upregulated in presurgery samples including sites for ETS-domain transcription factors ELK1, ELK4, and SPI1. The observed enrichment of these transcription factors binding sites in the ErbB/neuregulin pathways was more generally found in the complete upregulated presurgery gene list. The mRNAs encoding these 3 factors were not present in increased levels, suggesting an increased functional activation, likely by p38MAPK-mediated phosphorylation known to activate these factors. In this regard, we do find that the p38 mRNA expression level is significantly increased in presurgery samples (4, 22). ELK1 and ELK4 exhibit apparent, although not complete, redundancy in promoter binding (23) and each is implicated in important cellular growth processes (23). ELK1 has also been associated with activation of immunosuppressive TGF-β (24). The Spi1/Pu.1 transcription factor plays a crucial role in...
myeloid cell development in vertebrates (25) and regulates basal transcription in macrophages (26). We found that 123 genes identified as having ELK1-binding sites and which were also upregulated in presurgery samples were identical to those found to bind to ELK1 and/or ELK4 in extensive ChIP/Chip and ChIP:PCR studies (23), providing further support for our identification of these transcription factors as having an important regulatory role in the phenomenon we have identified.

DAVID (27) gene enrichment analysis of the differentially expressed genes with ETS-binding motifs identified 5 significant gene clusters having common functions including (i) genes with mitochondrial functions were significantly enriched in (111/139) in our presurgery upregulated gene list. Recent studies by Boros and colleagues (23) confirm the presence of ELK1- and ELK4-binding sites within a significant number of mitochondrial gene promoters. ELK1 has also been identified as a potential regulator of the DAP3 gene, upregulated in our presurgery samples and suggested to play an important role in mitochondrial maintenance (28). Other significant clusters included (ii) genes associated with protein biosynthesis machinery, (iii) RNA splicing genes, (iv) intracellular organelle lumen genes, and (v) genes associated with the regulation of translation. Genes associated with basal transcriptional machinery, such as RNA splicing, were also shown to be enriched for ELK1-binding sites by ChIP-seq (29), supporting the hypothesis that these 3 transcription factors are important to the presurgery transcription profiles we have identified.

**Repression/activation of genes from specific lymphoid cell types**

Because PBMC include diverse cell types, we asked whether changes in gene expression that occurred after tumor removal were primarily associated with a specific immune cell subset. For this purpose, we utilized the IRIS (30) database. IRIS classifies markers as cell type specific if they are expressed in a specific type or lineage of immune cells at levels 3-fold or more in other immune cells. We found that differentially expressed lymphoid-specific IRIS genes were mainly upregulated (58/71 genes, \( P = 0.002 \)) in pre- vs. postsurgery samples. Although the individual lymphoid categories of T-cell- and B-cell–specific genes did not show significant trends of increased or decreased expression, NK cell–specific genes were exclusively upregulated (12 of 12 genes, \( P = 0.006 \)) in the presurgery samples, in agreement with our pathway studies. Myeloid-specific genes were significantly downregulated (39 of 65 genes, \( P = 0.0001 \)) in presurgery samples. Genes specific for the individual myeloid lineages, monocytes, and dendritic cells showed no significant upward or downward expression trends. Neutrophils and other granulocytes are underrepresented in our purified PBMC samples and messages specific to those lineages are not found as significantly overrepresented (Table 2).

**Changes in PBMC gene expression in pre- versus postsurgery comparisons are similar to changes found in comparison of lung cancer patients to unrelated noncancer control patients**

To determine whether the removal of tumor(s) from lung elicit alterations in gene expression in PBMC that are similar to those we identified in comparing patients with malignant tumors versus control patients with nonmalignant lung disease (NHC), we carried out the following comparison. We first determined the overlap between the most informative SVM genes (\( n = 3,271 \)) found in pre-versus postsurgery comparison and the corresponding SVM list (\( n = 2,385 \)) found in comparing 127 samples of cancer patients to 91 noncancer patients in our previous study (9). We identified 751 genes changed significantly and in the same direction, versus only 254 expected by chance (\( P < 3 \times 10^{-56} \)). There is a highly significant correlation

---

**Table 2. Summary of differentially expressed genes specific to different classes of immune cells as defined by the IRIS database**

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Changed</th>
<th>Up</th>
<th>Down</th>
<th>Enrich-up</th>
<th>Enrich-down</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>T cell</td>
<td>7</td>
<td>3</td>
<td>4</td>
<td>0.67</td>
<td>1.58</td>
<td>0.3</td>
</tr>
<tr>
<td>Neutrophil</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>0.78</td>
<td>1.39</td>
<td>0.5</td>
</tr>
<tr>
<td>NK cell</td>
<td>12</td>
<td>12</td>
<td>0</td>
<td>\textbf{1.56}</td>
<td>0</td>
<td>\textbf{0.006}</td>
</tr>
<tr>
<td>Myeloid</td>
<td>65</td>
<td>26</td>
<td>39</td>
<td>0.63</td>
<td>\textbf{1.66}</td>
<td>\textbf{0.0001}</td>
</tr>
<tr>
<td>Multiple</td>
<td>152</td>
<td>89</td>
<td>63</td>
<td>0.92</td>
<td>1.15</td>
<td>0.2</td>
</tr>
<tr>
<td>Monocyte</td>
<td>13</td>
<td>6</td>
<td>7</td>
<td>0.72</td>
<td>1.49</td>
<td>0.2</td>
</tr>
<tr>
<td>Lymphoid</td>
<td>71</td>
<td>58</td>
<td>13</td>
<td>\textbf{1.28}</td>
<td>0.51</td>
<td>\textbf{0.002}</td>
</tr>
<tr>
<td>Dendritic cell</td>
<td>7</td>
<td>2</td>
<td>5</td>
<td>0.45</td>
<td>1.98</td>
<td>0.1</td>
</tr>
<tr>
<td>B cell</td>
<td>11</td>
<td>6</td>
<td>5</td>
<td>0.85</td>
<td>1.26</td>
<td>0.5</td>
</tr>
<tr>
<td>Non-Iris genes</td>
<td>2,923</td>
<td>1,868</td>
<td>1,055</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

NOTE: Bold indicates significant enrichments with \( P < 0.05 \) shown in italic.

Abbreviations: Up, upregulated in presurgery samples; Down, downregulated in presurgery samples; Enrich, enrichment of up or down genes.
Similarities in gene expression changes and relationship between different classes of PBMC samples. A, correlation of expression ratios (log2 values) for 751 genes identified both in the comparison of NSCLC to nonmalignant control patients (y-axis) and the pre- versus postsurgery lung cancer patients (x-axis). This similarity in differential gene expression in both studies suggests that information that distinguishes malignant and benign nodules in the previous study is also present in the pre versus postsurgery data. B, relationships between cancer and control sample classes. Classification (SVM) scores of various sample groups on the basis of 50 genes (Fig. 1) that were differentially expressed in pre- versus postsurgery PBMC from NSCLC patients. Whisker ends show full range of scores for each group; grey boxes include 50% range; horizontal line within each indicates median score. Number of samples in each class (from left to right) is 18, 127, 41, 50, and 18.

To determine whether we could identify those genes specific to the presence of a benign nodule, we compared 3,276 genes we previously found to be differentially expressed between patients with lung cancer and benign nodules (9), with the 3,271 genes differentially expressed in this pre- versus postsurgery analysis. We found a significant overlap of 789 \( (P = 3 \times 10^{-5}) \) suggesting the pre- versus postsurgery comparison should contain similar information that could distinguish malignant tumors from benign nodules. Confirmation that this is the case was obtained using SVM-RFE 10-fold crossvalidation to distinguish malignant tumors from nonmalignant nodules using only the 3,276 pre-versus postsurgery genes. This identified a 135-gene signature (not shown) which separated these 2 groups with 78% sensitivity and 71% specificity similar to the accuracy previously reported (9).

Altered expression of 5 miRNAs in pre- versus postsurgery samples

To assess whether miRNAs might function as diagnostic biomarkers and whether they could be responsible for some of the changes in mRNA levels detected, we compared miRNA expression levels in pre- and postsurgery PBMC samples from 11 of the pre- vs. postpairs for which sufficient RNA was available. By paired t test, we determined that 46 of the 643 miRNAs detected in PBMC were significantly differentially expressed between pre- and postsurgery samples (\( P < 0.05, \) FDR 42%), and that 42 of 46 (91%) were upregulated in the presurgery samples. Because our sample size was relatively small, we focused further investigation on 5 miRNAs that showed the most significant changes with a low FDR (15%). These included let-7c,
miR-34a, miR-202*, miR-769-5p, and miR-642 (Supplementary Fig S2). To identify pathways and functions potentially affected by these 5 miRNAs, we identified putative target genes on the basis of 2 criteria: (i) the gene was computationally predicted to be a target of a specific miRNA, and, (ii) expression of the target gene changed significantly between the pre- versus postsurgery samples, in the direction opposite to the expression of miRNA. For let-7c, miR-34a, miR-202*, miR-769-5p, and miR-642, we found 192, 214, 49, 129, and 184 genes, respectively (Supplementary Table S6), that fit both criteria, resulting in a combined list of 569 unique genes, a number significantly more than expected by chance \( (P = 6 \times 10^{-7}) \). This supports a model that includes these 5 miRNAs as important contributors to the observed effects of tumor presence on PBMC gene expression.

We identified functional enrichments among the potential targets, using DAVID (27) and Ingenuity (IPA) software. DAVID results indicated significant numbers of the genes were involved in transcription (51 genes; FDR = 0.1%) and apoptosis (21 genes; FDR = 0.1%). IPA analysis revealed that many of the miRNAs target transcription factors common to immunologically important pathways. The most frequently shared target genes among the 30 significantly altered the pathways were NFkB (25 pathways), RelA (21 pathways), cFos/cJun (24 pathways), and IKK (19 pathways; Supplementary Table S7). The most significant numbers of targets were in the gonadotropin releasing hormone pathway, IL-10 signaling, and the sphingosine-dependent apoptosis (20). Fourth, members of the ErbB/neuregulin pathway genes were also significantly different in the pre-versus postsurgery comparison.

Discussion

We show that a NSCLC elicits large-scale changes in gene expression in PBMC and that this influence on the peripheral immune cells is substantially reversible by tumor removal. The changes we find are clearly tumor associated and not attributable to the surgery per se as the gene expression changes detected after lung tumor removal are very similar to those found when comparing lung cancer patients with tumor-naive patients with smoking related nonmalignant lung disease. The use of matched postsurgery samples as our control class in these comparisons eliminates much of the variability inherent in comparisons with unrelated cancer-free controls. As a result, we are able to identify a set of differentially expressed genes which exhibit significant differences in expression levels, using only 18 sample pairs.

We also present evidence that nonmalignant lung nodules can also influence PBMC gene expression and identify a signature from the pre-versus postdifferentially expressed genes that can distinguish malignant tumors from nonmalignant nodules. Although validation studies are necessary, this gene signature can potentially be used to develop a noninvasive method to assess whether suspect lung nodules are indeed malignant. The effects of the tumor presence on the peripheral immune system are manifested as relatively small changes in expression levels of several thousand genes in PBMC. The majority of these PBMC genes (67%) were expressed at higher levels prior to tumor resection.

We also find that arms of the innate immune system thought to be important for tumor-directed immunity seem to be negatively influenced by the tumor presence. First, we find evidence that NK function may be suppressed, as transcript levels for repressive forms of NK cell-associated KIR receptors were consistently elevated before versus after tumor resection in peripheral immune cells. These receptors included KLRB1 (which acts through ceramide signaling, another highly affected pathway), KIR2DL3, KIR2DL1, KIR3DL1, KIR2DL5A, and KIR2DL2. Because inhibition is thought to be dominant over activation in the KIR system (13, 34), the combined results suggest that the functions of NK cells within the PBMC population studied are impaired in the presence of lung tumors. Second, the differentially expressed genes of myeloid cells important for an innate response were found to be predominantly downregulated prior to tumor removal. The majority of genes associated with chemotaxis of myeloid cells and glucocorticoid receptor signaling were also expressed at significantly lower levels prior to tumor resection, providing further indication of a suppressed state of the peripheral immune system in the presence of tumor.

Third, we found that components of the ceramide pathway were upregulated in patients with tumors, suggesting that the at least some PBMC cell types are primed for apoptosis which could impair an antitumor responses. Genes found to be upregulated in the presence of tumor included S1PR5 receptor as well as intracellular components of the ceramide pathway, reflecting multiple mechanisms driving sphingosine-dependent apoptosis (20). Fourth, members of the ErbB/neuregulin pathway genes were also significantly different in the pre-versus postsurgery comparison. ErbB receptors and Neuregulin-1 have also been shown to be expressed by NSCLC cell lines (35) suggesting that effects on expression of the ErbB pathway in PBMC of lung tumor patients may be caused by Neuregulin-1 synthesized by normal lung epithelium or lung tumors (36), or by the ErbB1 ligands such as amphiregulin or TGF-α, also produced by lung tumors (37).

We also find significant alterations in expression of 5 miRNAs in the presence versus absence of NSCLC tumors. A previous study comparing miRNA in PBMC from NSCLC and healthy controls (38) identified a series of 24 miRNAs that distinguish the 2 classes, included only let-7 of the 5 miRNAs we have identified. This may be attributed to the use of a healthy and younger control class in that comparison. In our study, the miRNAs most consistently differentially expressed, such as the coding genes, are primarily expressed at higher levels in the presence of the cancer. We identified potential targets for the 5 most significantly changed miRNAs among the differentially expressed genes that are downregulated in presurgery cancer patients and show that these 5 miRNAs primarily target differentially
expressed transcription factors found in our dataset. Among the pathways showing significant tumor-associated effects that also included significant numbers of potential miRNA targets are the toll-like receptor (TLR)-associated pathways. We find a significant decrease in message levels in presurgery samples for TLRs 5, 6, 7, 8, and 10 as well as messages for the TLR2 and TLR4 accessory molecule CD14 and the TLR signaling components MYD88 and TOLLIP generally required for all TLR signaling. Several key transcriptional regulators of TLR signaling (Fig. 4) are targeted by 1 to 4 of the 5 miRNAs overexpressed presurgery. For example, 4 of the 5 miRNAs target IKKα and the NFkB complex, important to many immune response pathways. Targeting is via both perfect and imperfect matches suggesting both transcript degradation and translational arrest mechanisms are in play (reviewed in ref. 39). Although none of the miRNAs target the TLR genes directly, expression of several TLRs is also regulated by NFκB (40, 41),

Figure 4. Model showing the integration of mRNA and miRNA expression data associated with TLR signaling pathway. Blue symbols indicate that a gene is underexpressed and red symbols indicate that a gene is overexpressed in the presurgery compared with the postsurgery samples, grey symbols indicate that a gene is not differentially expressed, orange circles indicate that a gene is targeted by 1 or more of the 5 miRNAs, each represented by a black symbol on the circle. LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase.
suggesting miRNA targeting can secondarily affect TLR expression. Although the changes in mRNA expression levels for each targeted gene are generally small, the resulting effects on translation and the cumulative effects of targeting multiple points in the signal transduction pathway could be substantial.

Members of the TLR family play key roles in both innate and adaptive immune responses associated with infections, autoimmune conditions, inflammatory lung diseases, and in the regulation of tolerance (reviewed in refs. 42, 43). A decrease of TLR-mediated responses, in concert with the miRNA-mediated inhibition of key transcription factors required for TLR signal transduction pathways, would impair important immune regulatory functions associated with immune defense in patients with lung tumors.

An important question raised by our findings of diagnostic lung tumor–associated biomarkers in PBMC concerns the mechanisms by which lymphocyte gene expression is influenced. There have been a large number of studies focused on the identification of LC-derived proteins in serum or plasma, including circulating autoantibodies and a number of proteins with known effects on immune cells (reviewed in refs. 44, 45). A recent study by Ostroff and colleagues (46) identified a panel of 44 plasma proteins whose levels were significantly different between mostly early-stage NSCLC patients and control groups of high-risk smoker controls (46). We are likely measuring the effects in the periphery of proteins or small RNAs derived from the tumor and/or its microenvironment. Long-range effects of both premalignant lung lesions on bone marrow macrophages that are enhanced by tumor progression have been reported previously (47–49). Previous studies have also shown that TGF-α synthesized by lung tumors (37) can activate ErbB, which lies on a pathway to ELK1 activation. Transcription factors ELK1-, ELK4-, and SPI1-binding motifs were enriched, on average, by 23% within the promoters of the genes found to be upregulated in PBMC prior to tumor resection. These observations of crosstalk between tumor and the peripheral host immune system suggest mechanisms for generating the changes in biomarker expression we have detected, observations that might potentially be exploited for development of more effective immune therapy.

Many of the changes in gene expression within PBMC detected in patients bearing lung tumors were common to both benign nodules and malignant tumors. The benign nodules, histologically diagnosed as nonmalignant, were typical of high-risk nodules that require biopsy to confirm their nonmalignant status. Understanding the basis for the differences that distinguish PBMC from patients with malignant tumors from patients with benign nodules could provide an important additional tool for early detection and control of lung cancer. Although this study is relatively small, the increased robustness of the comparisons using the postsurgery samples as the highly matched control class and the successful application of the derived signatures to new NSCLC samples indicates the feasibility of this approach for biomarker discovery. Although the analysis of the tumors themselves remains an important pursuit, our approach provides the opportunity for continued noninvasive surveillance after tumor removal and provides important added information on the interactions of benign nodules and malignant lung tumors with the immune system.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Mea Fuller for excellent editorial assistance.

Grant Support

This project was supported by PA DOH Tobacco Settlement grant SAP 4100020718, the PA DOH Commonwealth Universal Research Enhancement Program, EDRN set-aside funds for U01CA86137, and the Wistar Cancer Center Support Grant P30 CA010815. A. Vachani was supported by NCI Kit CA111952. A.V. Kossenkov was supported by NCI T32 CA 09171. The project used the Wistar Genomics and Bioinformatics facilities supported by P30 CA010815.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 18, 2011; revised May 19, 2011; accepted July 14, 2011; published OnlineFirst August 1, 2011.

References

Lung Cancer and the Peripheral Immune System


www.aacajournals.org
Clin Cancer Res; 17(18) September 15, 2011
5877

Published OnlineFirst August 1, 2011; DOI: 10.1158/1078-0432.CCR-11-0737

Downloaded from clinicalcancers.aacrjournals.org on April 29, 2021. © 2011 American Association for Cancer Research.
Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System

Andrew V. Kossenkov, Anil Vachani, Celia Chang, et al.

Clin Cancer Res 2011;17:5867-5877. Published OnlineFirst August 1, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-0737

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/08/01/1078-0432.CCR-11-0737.DC1

Cited articles
This article cites 48 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/18/5867.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/17/18/5867.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/17/18/5867.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.